Mayne Pharma Group (ASX:MYX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

MYX 주식 개요

전문 제약 회사인 Mayne Pharma Group Limited는 호주, 뉴질랜드, 미국, 캐나다, 유럽, 아시아 및 전 세계에서 브랜드 및 제네릭 의약품을 제조 및 판매하는 회사입니다.

MYX 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	1/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 15.65% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Mayne Pharma Group Limited 경쟁사

Argenica Therapeutics

ASX:AGN

AU$96.8m

Incannex Healthcare

ASX:IHL

AU$65.1m

Vita Life Sciences

ASX:VLS

AU$128.4m

PharmAust

ASX:PAA

AU$77.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Mayne Pharma Group
과거 주가
현재 주가	AU$4.71
52주 최고치	AU$7.46
52주 최저치	AU$2.75
베타	1.21
11개월 변경	-6.18%
3개월 변경 사항	-34.94%
1년 변경 사항	7.05%
33년 변화	-27.54%
5년 변화	-55.98%
IPO 이후 변화	-60.75%

최근 뉴스 및 업데이트

Recent updates

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 06

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Mar 01

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Nov 16

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

Nov 10

Mayne Pharma Group (ASX:MYX) Is Carrying A Fair Bit Of Debt

May 17

Is Mayne Pharma Group Limited (ASX:MYX) Trading At A 37% Discount?

Mar 22

How Many Mayne Pharma Group Limited (ASX:MYX) Shares Did Insiders Buy, In The Last Year?

Mar 01

What You Need To Know About Mayne Pharma Group Limited's (ASX:MYX) Investor Composition

Feb 08

Mayne Pharma Group Limited's (ASX:MYX) Shift From Loss To Profit

Jan 18

Mayne Pharma Group's (ASX:MYX) Shareholders Are Down 75% On Their Shares

Dec 27

Would Mayne Pharma Group (ASX:MYX) Be Better Off With Less Debt?

Dec 09

A Quick Analysis On Mayne Pharma Group's (ASX:MYX) CEO Compensation

Nov 24

주주 수익률

	MYX	AU Pharmaceuticals	AU 마켓
7D	2.2%	6.4%	-0.3%
1Y	7.0%	72.4%	8.3%

수익률 대 산업: MYX 지난 1년 동안 64.4 %를 반환한 Australian Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: MYX 지난 1년 동안 8.9 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is MYX's price volatile compared to industry and market?
MYX volatility
MYX Average Weekly Movement	6.4%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	8.2%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	3.2%

안정적인 주가: MYX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: MYX 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2005	n/a	Shawn O’Brien	www.maynepharma.com

전문 제약 회사인 Mayne Pharma Group Limited는 호주, 뉴질랜드, 미국, 캐나다, 유럽, 아시아 및 국제적으로 브랜드 및 일반 의약품을 제조 및 판매하는 회사입니다. 이 회사는 네 가지 부문으로 운영됩니다: 국제 브랜드 제품 및 포트폴리오 제품 부문. 경구용 약물 전달 시스템, 타사 고객에게 계약 개발 및 제조 서비스를 제공하고 피부과, 여성 건강 및 전염병 치료 분야의 전문 의약품을 유통합니다.

Mayne Pharma Group Limited 기본 사항 요약

Mayne Pharma Group 의 수익과 매출은 시가총액과 어떻게 비교하나요?
MYX 기본 통계
시가총액	AU$382.21m
수익(TTM)	-AU$274.18m
수익(TTM)	AU$319.28m

1.2x

P/S 비율

-1.4x

P/E 비율

MYX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
MYX 손익 계산서(TTM)
수익	AU$319.28m
수익 비용	AU$145.07m
총 이익	AU$174.21m
기타 비용	AU$448.39m
수익	-AU$274.18m

최근 보고된 수익

Dec 31, 2023

다음 수익 날짜

Aug 23, 2024

주당 순이익(EPS)	-3.38
총 마진	54.56%
순이익 마진	-85.87%
부채/자본 비율	5.5%

MYX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

MYX 주식 개요

보상

위험 분석

Mayne Pharma Group Limited 경쟁사

ASX:AGN

AU$96.8m

ASX:IHL

AU$65.1m

ASX:VLS

AU$128.4m

ASX:PAA

AU$77.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Recent updates

No longer forecast to breakeven

New minor risk - Profitability

Consensus revenue estimates increase by 14%, EPS downgraded

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Consensus estimates of losses per share improve by 13%

Mayne Pharma Group Limited Approves Election of Anne Lockwood

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Independent Non-Executive Director recently bought AU$69k worth of stock

Consensus estimates of losses per share improve by 13%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

Independent Non-Executive Chairman recently bought AU$74k worth of stock

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Consensus revenue estimates fall by 19%

Price target decreased by 24% to AU$3.86

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Consensus revenue estimates fall by 11%

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

Analysts Just Slashed Their Mayne Pharma Group Limited (ASX:MYX) EPS Numbers

Consensus forecasts updated

Price target decreased to AU$0.37

Is Mayne Pharma Group (ASX:MYX) Using Too Much Debt?

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Price target decreased to AU$0.40

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

Price target increased to AU$0.43

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Price target decreased to AU$0.36

Is Mayne Pharma Group (ASX:MYX) A Risky Investment?

Things Look Grim For Mayne Pharma Group Limited (ASX:MYX) After Today's Downgrade

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 97%

Mayne Pharma Expands U.S Dermatology Portfolio

Price target increased to AU$0.48

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

We Think Mayne Pharma Group Limited's (ASX:MYX) CEO Compensation Package Needs To Be Put Under A Microscope

Mayne Pharma Group (ASX:MYX) Is Making Moderate Use Of Debt

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company